Phase 1 Relapsed/Refractory Multiple Myeloma Clinical Trials
11 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled83 locationsNCT04973605
Recruiting
Phase 1Phase 2
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals186 enrolled7 locationsNCT06669247
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA200 enrolled32 locationsNCT05862012
Recruiting
Phase 1Phase 2
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Phase 1Phase 2
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Nanjing Leads Biolabs Co.,Ltd342 enrolled26 locationsNCT06049290
Recruiting
Phase 1
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma(MM)
Xi'an No.3 Hospital18 enrolled1 locationNCT07139509
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Caribou Biosciences, Inc.50 enrolled16 locationsNCT05722418
Recruiting
Phase 1
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Chunrui Li18 enrolled1 locationNCT05219721
Recruiting
Phase 1
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.12 enrolled1 locationNCT05759793
Recruiting
Phase 1Phase 2
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
Advanced Solid TumorsRelapsed/Refractory Multiple MyelomaRelapsed/Refractory Non-Hodgkin Lymphoma
GI Cell, Inc.50 enrolled4 locationsNCT05880043